Novel Rx
Janet Pope Janetbirdope
4 years 3 months ago
Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari >Adalimumab for pain, HAQ, am stiffness but = on fatigue. POS0649 @RheumNow @eular_org #EULAR2021
Janet Pope Janetbirdope
4 years 3 months ago
Who responds better to bDMARDs in RA, PsA & SpA? Men, women or equal? POS0208 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope
4 years 3 months ago
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 3 months ago
2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU
Robert B Chao, MD doctorRBC
4 years 3 months ago
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab
⭐️mean change and resolution of enthesitis similar
⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity
⭐️rate of relapse ⬇️ and similar
Abs#POS0194
#EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Paul Studenic Stiddyo
4 years 3 months ago
#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results
PE: ACR20 51% active vs 26% on PLC
PASI90: 55% active vs. 10% PLC
#EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
Andy Vermaut AndyVermaut
4 years 3 months ago
BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares https://t.co/dUJMKFkZ52 https://t.co/oAgKcGbW0k
Janet Pope Janetbirdope
4 years 3 months ago
Difficult to treat RA pts cycle through more advanced therapies! Kind of obvious but in N=363, 9.4% with advanced Rx were difficult to treat vs 39% if > 1 ts\bDMARDs. Worse pts had ⬆️disease duration. Drug resistance over time? POS0405 @RheumNow #EULAR2021 @eular_org
Dr. John Cush RheumNow
4 years 3 months ago
Blindness with Tocilizumab in GCA: Is it a Worry? Dr. David Liew ( @drdavidliew )
#EULAR2021
https://t.co/xokPqGMEyA https://t.co/NJ3PrFR6nF
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
1. EULAR2021 - Day2a
2. EULAR2021 - Day2b
Janet Pope Janetbirdope
4 years 3 months ago
JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy in 320 Rxs in 215 pts JAKi lasted longer adjusting for age, sex, RA duration & line of therpy & 1st line Rx POS0205 #EULAR2021 @RheumNow https://t.co/4m2RXBkTDr
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
The second day of EULAR 2021 took a big leap in online content. #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty.
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr.
Poster Hall